FIGURE 2.

Schematic representation of T cell-based immunotherapies. (A) Due to its dual specificity for CD3 and PSCA, the CD3-PSCA bsAb is able to cross-link T cells and PSCA-expressing tumor cells. Subsequently, T cells are activated and kill the recognized target cell. (B) The UniCAR system is composed of UniCAR T cells and TAA-specific TMs. In the absence of TMs, UniCAR T cells are not activated. Upon addition of a PSCA-specific TM, UniCAR T cells can be cross-linked with PSCA-expressing tumor cells resulting in an efficient tumor cell lysis.